文献速递外周动脉疾病

健康猪模型:DCB后置入Zilver PTX药物洗脱支架的安全性

Safety of Zilver PTX Drug-Eluting Stent Implantation Following Drug-Coated Balloon Dilation in a Healthy Swine Model.
PubMed 文献 · J Endovasc Ther · 2017-11-21

在20只健康猪髂股动脉模型中,比较药物涂层球囊(DCB)扩张后置入Zilver PTX药物洗脱支架与常规球囊(BA)后置入的安全性;随访1、3、6个月,两组安全参数(炎症、内皮细胞丢失)无显著差异,DCB+DES组3个月纤维蛋白百分比显著更高,但总体提示DCB后置入Zilver PTX支架是安全的。

要点

  • 健康猪髂股动脉模型中,DCB后置入Zilver PTX支架与BA后置入相比安全参数无显著差异。
  • DCB+DES组3个月纤维蛋白百分比显著高于BA+DES组,但组间各时间点趋势一致。
  • 下游组织仅DCB组观察到紫杉醇相关纤维蛋白样坏死,提示需关注远端栓塞风险。

核心结论

  • 本临床前研究提示,DCB扩张后置入Zilver PTX支架是安全的策略,可考虑用于DCB治疗后需要支架的患者。

研究设计与样本

  • 在20只健康猪的非病变髂股动脉中,比较DCB后置入DES(DCB+DES)与BA后置入DES(BA+DES),于1、3、6个月处死,通过血管造影和组织学评估安全性。

主要发现

  • 两组在各时间点的炎症和内皮细胞丢失等安全参数无显著差异。
  • DCB+DES组3个月纤维蛋白百分比显著高于BA+DES组[20.0%(IQR 11.6, 28.4) vs 4.2%(IQR 1.4, 9.6),p=0.04],组间各时间点趋势一致。
  • 中膜平滑肌细胞丢失在1个月达峰,各时间点组间无统计学差异,但DCB+DES组丢失更明显。
  • 下游组织小动脉紫杉醇相关纤维蛋白样坏死仅见于DCB组,1个月为14.3%切片,3个月为11.5%。

关键数值与推荐

  • 每切片未覆盖支架 strut 百分比不得超过30%,内皮细胞丢失须小于50%。

临床怎么用

  • 对于DCB治疗后需要支架的病例,可考虑置入Zilver PTX支架,但需关注纤维蛋白沉积和远端栓塞风险。

局限性

  • 本研究为健康猪模型,非病变血管,结果不能直接外推至人类病变血管。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the safety of Zilver PTX drug-eluting stents (DES) following drug-coated balloon (DCB) angioplasty or conventional balloon angioplasty (BA) in a healthy porcine iliofemoral artery model. METHODS: DES implantation following DCB (DCB+DES) or BA (BA+DES) was assessed by angiography and histology in the nondiseased iliofemoral arteries of 20 animals, with sacrifice at 1, 3, and 6 months. Safety assessment compared quantitative measures of vessel integrity (eg, preservation of artery geometry, structure, and lumen dimensions; absence of aneurysm; malapposition) and histological parameters (eg, excessive inflammation). The percentage of uncovered struts could not be >30% per section and the endothelial cell loss had to be <50%. The vascular and skeletal muscle changes in the downstream regions were also assessed histologically for evidence of emboli. RESULTS: No significant differences in safety parameters, including inflammation and endothelial cell loss, were observed between the 2 groups at all time points. Percentage of fibrin was significantly higher in DCB+DES at 3 months [20.0% (IQR 11.6, 28.4) vs BA+DES 4.2% (IQR 1.4, 9.6), respectively; p=0.04], with consistent trends between groups at all time points. Medial smooth muscle cell loss peaked at 1 month and was not statistically different between groups at any time point, although the loss was greater in the DCB+DES group. Sections with arterioles exhibiting paclitaxel-associated fibrinoid necrosis in downstream tissues were observed exclusively in the DCB group at 1 month (14.3% of sections) and 3 months (11.5%). CONCLUSION: This preclinical study suggests that Zilver PTX stent implantation is a safe strategy after DCB angioplasty and might be considered for patients who require stenting after DCB treatment.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Torii S, Yahagi K, Mori H, et al. Safety of Zilver PTX Drug-Eluting Stent Implantation Following Drug-Coated Balloon Dilation in a Healthy Swine Model. J Endovasc Ther. 2017. PMID: 29161933. doi:10.1177/1526602817743747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。